Role of MRD Status in Relation to Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients: A Meta-Analysis

Details

• Personal Author:
  Boulad M ; Devlin S ; Landgren O ; Mailankody S
• Description:
  Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and necessary step forward, clinical studies have explored strategies to detect minimal residual disease (MRD) and its correlation with clinical outcomes. In this context, MRD has been proposed as a regulatory end point for drug approval in newly diagnosed multiple myeloma. To better define the role of MRD negativity in relation to clinical outcomes, we undertook a meta-analysis including published clinical trials of newly diagnosed multiple myeloma patients. We applied a random effects model which weighted studies using the inverse-variance method. Studies were combined on the scale of the logarithm of the hazard ratio (HR) and the corresponding s.d. We found that MRD negativity (versus positivity) was associated with better PFS (HR=0.35; 95% confidence interval (CI) 0.27-0.46; P<0.001) and overall survival (HR=0.48; 95% CI 0.33-0.70; P<0.001). Our results show that MRD negativity is a strong predictor of clinical outcomes, supportive of MRD becoming a regulatory end point for drug approval in newly diagnosed multiple myeloma. [Description provided by NIOSH]
• Subjects:
  Blood Diagnosis Drug Therapy Neoplasms Occupational Health Safety
• Keywords:
  Blood Cells Bone Marrow Cancer Cell Alteration Clinical Diagnosis Clinical Techniques Clinical Tests Disease Control Diseases Drugs Drug Therapy Hematopoietic System Myeloid Tissue Stem Cells Survival Rate

  More +
• ISSN:
  0268-3369
• Document Type:
  Text
• Funding:
  Cooperative Agreement
• Genre:
  Journal Article
• Place as Subject:
  New York ; OSHA Region 2
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  51
• Issue:
  12
• NIOSHTIC Number:
  nn:20050743
• Citation:
  Bone Marrow Transplant 2016 Dec; 51(12):1565-1568
• Contact Point Address:
  Professor O Landgren, Department of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
• Email:
  landgrec@mskcc.org
• Federal Fiscal Year:
  2017
• Performing Organization:
  Albert Einstein College of Medicine, Inc., Bronx, New York
• Peer Reviewed:
  True
• Start Date:
  20170701
• Source Full Name:
  Bone Marrow Transplantation
• End Date:
  20200630
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:d6c6217364976a52f40a0420393bc12f553dc1e87bed644e08738ddb27d875cd14c6af6127496c2194934aed5216d703e152974d9e4f464fc50a13a8c82c276f
• Download URL:
  https://stacks.cdc.gov/view/cdc/210968/cdc_210968_DS1.pdf
• File Type:
  [PDF - 305.00 KB ]